SOCS调控炎症反应防治心脏瓣膜钙化机制研究
批准号:
81270297
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
董念国
依托单位:
学科分类:
H0208.心脏瓣膜疾病和心包疾病
结题年份:
2016
批准年份:
2012
项目状态:
已结题
项目参与者:
李军、桂平、李飞、张巧、洪昊、陈思、李华东、孙永丰、张超
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
心脏瓣膜钙化严重危害人类健康,其发病机制目前尚不明确。本课题组前期实验及诸多研究表明:慢性炎症反应在瓣膜钙化启动和进展中起重要作用;单核巨噬细胞在不同微环境刺激下极化为不同功能表型,调控局部炎症反应;JAK-STAT信号转导是炎症因子发挥效应的共同通路,广泛参与细胞增殖、分化、凋亡及免疫调节等病理生理过程;SOCS是JAK-STAT信号通路的靶基因,通过负性调控减少炎症因子及凋亡基因等表达。鉴于此,我们推测:JAK-STAT信号通路可能参与心脏瓣膜钙化的病理过程,SOCS通过抑制JAK-STAT基因表达,影响炎症反应,干预瓣膜钙化的发生发展。本项目拟通过检测人体钙化瓣膜,构建瓣膜钙化动物和细胞模型,利用shRNA体内基因沉默技术,可控性施加干预措施,探讨SOCS调控JAK-STAT信号转导通路在瓣膜炎症反应及瓣膜钙化中的作用及分子机制,为药物防治天然或生物瓣膜钙化提供新思路。
英文摘要
Heart valve calcification is a common clinical problem with high morbidity and mortality, and to date there are no effective drug therapy or preventive methods for it. In the past decade, an abundance of evidence have suggested that, valve calcification is not simply a passive degenerative disease, but an active pathological progress akin to atherosclerosis, including endothelial dysfunction ,lipoprotein deposition, chronic inflammation, extracellular matrix remodeling. The crucial role of chronic inflammation in valve calcification has been widely documented. Nevertheless, mechanism for chronic inflammation on valve biology is far from being fully understood..Macrophage and inflammatory cytokines constitute the main part of chronic inflammation. Depending on the microenvironment, macrophages can polarize to distinct functional phenotypes: pro-inflammatory classically activated macrophages (M1 macrophages) and anti-inflammatory alternatively activated macrophages (M2 macrophages). Recent studies demonstrate that the ratio of M1/M2 macrophages was positively correlated with the severity of coronary atherosclerosis, whereas the association between macrophage polarization and valve calcification has not been defined. Most cytokines use the so-called janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway, and this pathway also acts as a key regulator in macrophage polarization. Therefore, JAK-STAT controls the important inflammatory process. Altogether, these indicate that JAK-STAT signaling pathway may participate the pathogenesis of valve calcification..Suppressors of cytokine signaling (SOCS) proteins are target genes of JAK-STAT pathway, and they play pivotal role in negative regulation of JAK-STAT. Accumulating evidence shows that dysregulation of cytokine signaling by differential SOCS expression, especially SCOS1 and SOCS3, is involved in various inflammatory, immune and infectious diseases. SOCS were found highly expressed both in human atherosclerotic plaques and in experimental atherosclerosis. And SOCS3 knockdown exacerbate the atherosclerotic process in apoE-/- mice by increasing the size, macrophage content and chemokines expression in the lesions. All these were accompanied by STAT1/STAT3 activation. In view of the similarities between heart valve calcification and atherosclerosis, negative regulation of JAK-STAT by SOCS seems a promising intervention for alleviating valve calcificaion. .In this project, we are aiming to investigate: whether SOCS plays a pivotal role in the pathogenesis of valve calcification by regulating inflammatory reactions through JAK-STAT signaling pathway.
心脏瓣膜钙化严重危害人类健康,是多种因素共同调节的主动过程,其发病机制目前尚不明确。JAK-STAT信号转导是炎症因子发挥效应的共同通路,广泛参与细胞增殖、分化、凋亡及免疫调节等病理生理过程;而SOCS是JAK-STAT信号通路的靶基因,通过负性调控减少炎症因子及凋亡基因等表达。本课题组重点研究SOCS蛋白是否参与负性调控主动脉瓣钙化,并同时研究巨噬细胞极化是否参与瓣膜钙化过程。.课题组重点对SOCS3及JAK2/STAT3通路进行深入研究后发现,SOCS3在钙化主动脉瓣膜中高表达。LPS可刺激瓣膜间质细胞(VICs)中SOCS3高表达。而SOCS3高表达可显著降低VICs成骨样分化能力,并抑制其成钙能力。SOCS3同时可以通过IL-6介导的JAK2/STAT3通路发挥其负性调控作用。基于上述结果,我们可以继续深入研究,如何更好的调节SOCS3的表达,使其可以负向调控主动脉瓣瓣膜钙化过程并减轻瓣膜钙化,抑制其成骨样变速度,控制其钙化进展。最终达到提前预防治疗主动脉瓣钙化疾病的问题。.课题组同时对巨噬细胞极化是否参与瓣膜钙化进行深入研究。单核-巨噬细胞在不同微环境刺激下极化为不同功能表型,调控局部炎症反应,并且参与瓣膜钙化全过程,其中M1型巨噬细胞及其产物可刺激瓣膜间质细胞钙化,促进瓣膜钙化的发生和发展,而M2型巨噬细胞则未表现出促钙化特性。M1型巨噬细胞在钙化瓣膜上高表达,并且取M1型巨噬细胞上清液与VICs共培养,证实其分泌细胞因子等产物可促进VICs成骨样变,增强其成钙能力。基于上述结果,可以继续深入研究调控M1型巨噬细胞极化方向,通过减少M1型巨噬细胞,达到减轻瓣膜钙化,减轻瓣膜间质细胞成骨样分化,减轻其成钙能力。最终提前干预,达到防治主动脉瓣钙化疾病的目的。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Lazaroid U-74389G inhibits the osteoblastic differentiation of IL-1 beta-indcued aortic valve interstitial cells through glucocorticoid receptor and inhibition of NF-kappa B pathway
Lazaroid U-74389G 通过糖皮质激素受体和抑制 NF-κ B 通路抑制 IL-1 β 诱导的主动脉瓣间质细胞的成骨细胞分化
DOI:--
发表时间:2015
期刊:Journal of Steroid Biochemistry and Molecular Biology
影响因子:4.1
作者:Li, Huadong;Li, Geng;Liu, Yi;Dong, Nianguo
通讯作者:Dong, Nianguo
High-mobility group box-1 protein induces osteogenic phenotype changes in aortic valve interstitial cells
高迁移率group box-1蛋白诱导主动脉瓣间质细胞成骨表型变化
DOI:10.1016/j.jtcvs.2015.09.077
发表时间:2016-01-01
期刊:JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
影响因子:6
作者:Wang, Bo;Li, Fei;Dong, Nianguo
通讯作者:Dong, Nianguo
RAGE deficiency alleviates aortic valve calcification in ApoE-/- mice via the inhibition of endoplasmic reticulum stress
RAGE缺陷通过抑制内质网应激减轻ApoE(-/-)小鼠的主动脉瓣钙化
DOI:10.1016/j.bbadis.2016.12.012
发表时间:2017-03-01
期刊:BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
影响因子:6.2
作者:Wang, Bo;Cai, Zhejun;Li, Fei
通讯作者:Li, Fei
The Role of High Mobility Group Box 1 Protein in Interleukin-18-Induced Myofibroblastic Transition of Valvular Interstitial Cells
高迁移率族盒 1 蛋白在白细胞介素 18 诱导的瓣膜间质细胞肌纤维母细胞转变中的作用
DOI:10.1159/000447483
发表时间:2016-07
期刊:Cardiology
影响因子:1.9
作者:Xianming Zhou;Hua Xiao;Nianguo Dong;Fei Li
通讯作者:Fei Li
Oxidized Low-Density Lipoprotein Promotes Osteoblastic Differentiation of Valvular Interstitial Cells through RAGE/MAPK
氧化低密度脂蛋白通过RAGE/MAPK促进瓣膜间质细胞成骨分化
DOI:10.1159/000369126
发表时间:2015-01-01
期刊:CARDIOLOGY
影响因子:1.9
作者:Li, Fei;Zhao, Zhihong;Liu, Yi
通讯作者:Liu, Yi
免疫调节性生物材料诱导心脏瓣膜原位再生的机制研究
- 批准号:81930052
- 项目类别:重点项目
- 资助金额:297万元
- 批准年份:2019
- 负责人:董念国
- 依托单位:
基于MTC技术探讨整合素αvβ3力学传导调控VICs钙化机制研究
- 批准号:81873503
- 项目类别:面上项目
- 资助金额:57.0万元
- 批准年份:2018
- 负责人:董念国
- 依托单位:
组织引导性生物材料激活干细胞调控心脏瓣膜再生机制研究
- 批准号:31330029
- 项目类别:重点项目
- 资助金额:275.0万元
- 批准年份:2013
- 负责人:董念国
- 依托单位:
"组织工程化"模型探讨剪切力诱导心脏瓣膜钙化的机制研究
- 批准号:81170214
- 项目类别:面上项目
- 资助金额:50.0万元
- 批准年份:2011
- 负责人:董念国
- 依托单位:
枝化状PEG修饰去细胞瓣构建组织工程心脏瓣膜支架机制研究
- 批准号:30872540
- 项目类别:面上项目
- 资助金额:31.0万元
- 批准年份:2008
- 负责人:董念国
- 依托单位:
构建新型复合支架调控组织工程瓣膜力学性能机制研究
- 批准号:30571839
- 项目类别:面上项目
- 资助金额:27.0万元
- 批准年份:2005
- 负责人:董念国
- 依托单位:
生物信号调控天然支架组织工程瓣膜力学强度
- 批准号:30371414
- 项目类别:面上项目
- 资助金额:20.0万元
- 批准年份:2003
- 负责人:董念国
- 依托单位:
国内基金
海外基金















{{item.name}}会员


